Continued Treatment With SKY-0515 for People With Huntington's Disease
Tests SKY-0515, taken by mouth, in adults with Huntington's disease from an earlier study.
Key facts
- Who runs it
- Skyhawk Therapeutics, Inc.
- Where
- Auckland, Christchurch, and Wellington, New ZealandSee the 3 sitesAlso in 1 other country, 7 sites
- Trial code
- Registry title
- An Extension of SKY-0515 in Participants With Huntington's Disease
- Status
- Enrolling by invitation
- Phase
- Phase 2/3
- People taking part
- 500 people, planned
- Started
- 10 Apr 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- SKY-0515
- Record updated
- 24 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Huntington's disease who finished an earlier SKY-0515 treatment study and followed its procedures. They take the oral drug SKY-0515 in this extension.
- Age
- 25 years and older
- Sex
- Men and women can join.
- Disease stage
- Huntington's disease confirmed by genetic testing (as stated in the summary).
- Earlier treatment
- Must have finished treatment in an earlier SKY-0515 study and followed its procedures.
- Biomarker or test result
- Huntington's disease confirmed by genetic testing.
Main reasons for not taking part
- Any other condition that the investigator or sponsor thinks makes joining unsuitable or could stop the person from completing the study.
- Cannot tolerate blood draws.
- Cannot or will not attend all scheduled visits and follow the study procedures.
- Women who can have children without a negative pregnancy test or without two types of birth control.
- Men who will not use birth control during the study and for 90 days after the last dose.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Must have completed treatment in a prior SKY-0515 treatment study and, in the opinion of the Investigator, have been compliant with the prior SKY-0515 treatment protocol study procedures
- Must be able and willing to meet all study requirements in the opinion of the Investigator including:
- Participants must be able to tolerate blood draws
- Willing and able to comply with all scheduled visits, treatment plans,laboratory tests and other study procedures
- Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug
- Men must agree to use birth control during the study and for 90 days after the last dose
Who cannot take part
- -Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study
Where in New Zealand
Also in 1 other country, 7 sites
- Huntington's Disease AssociationAuckland, New ZealandEnrolling by invitation
- New Zealand Brain and Research InstituteChristchurch, New ZealandEnrolling by invitation
- Wellington HospitalWellington, New ZealandEnrolling by invitation
About the trial
What the trial wants to find out
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
The group in the trial
- 9mg doseTreatment being tested
Drug: SKY-0515 Type: Small molecule Route of Administration: Oral Dosage Frequency: Once daily Duration: until study drug is approved or study is discontinued Use: Experimental
Treatment: SKY-0515
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open Label Extension of SKY-0515 in Participants With Huntington's Disease Who Completed a Prior SKY-0515 Treatment Study
- Plain-language title
- Continued Treatment With SKY-0515 for People With Huntington's DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 24 July 2026